Literature DB >> 15310459

Id genes and proteins as promising targets in cancer therapy.

Sylvia Fong1, Robert J Debs, Pierre-Yves Desprez.   

Abstract

Since the identification of Id proteins more than a decade ago, much work has demonstrated their regulatory roles in development, cell fate and lineage determination, proliferation, differentiation, angiogenesis, invasion and migration. Recent studies reveal not only that Id protein expression is significantly correlated both with cancer progression and with overall prognosis, but also that it can be exploited as a therapeutic target. This review will focus on the recent advances in our understanding of the relationships between Id expression and cancer, as well as providing a rationale for developing therapeutic strategies using Ids as targets to treat metastatic cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310459     DOI: 10.1016/j.molmed.2004.06.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  47 in total

1.  The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma.

Authors:  Seung-Hee Lee; Ergeng Hao; Alice Kiselyuk; James Shapiro; David J Shields; Andrew Lowy; Fred Levine; Pamela Itkin-Ansari
Journal:  Mol Cancer Res       Date:  2011-04-15       Impact factor: 5.852

2.  Protein kinase Cα signaling regulates inhibitor of DNA binding 1 in the intestinal epithelium.

Authors:  Fang Hao; Marybeth A Pysz; Kathryn J Curry; Kristin N Haas; Steven J Seedhouse; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

3.  Cheminformatics models based on machine learning approaches for design of USP1/UAF1 abrogators as anticancer agents.

Authors:  Divya Wahi; Salma Jamal; Sukriti Goyal; Aditi Singh; Ritu Jain; Preeti Rana; Abhinav Grover
Journal:  Syst Synth Biol       Date:  2015-01-30

4.  Identification of Id1 as a downstream effector for arsenic-promoted angiogenesis via PI3K/Akt, NF-κB and NOS signaling.

Authors:  Chun-Hao Tsai; Ming-Hui Yang; Amos C Hung; Shou-Cheng Wu; Wen-Chin Chiu; Ming-Feng Hou; Yu-Chang Tyan; Yun-Ming Wang; Shyng-Shiou F Yuan
Journal:  Toxicol Res (Camb)       Date:  2015-10-05       Impact factor: 3.524

5.  Effects of upregulation of Id3 in human lung adenocarcinoma cells on proliferation, apoptosis, mobility and tumorigenicity.

Authors:  F-F Chen; Y Liu; F Wang; X-J Pang; C-D Zhu; M Xu; W Yu; X-J Li
Journal:  Cancer Gene Ther       Date:  2015-09-18       Impact factor: 5.987

6.  Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Authors:  Liliana Soroceanu; Ryuichi Murase; Chandani Limbad; Eric Singer; Juanita Allison; Isabel Adrados; Rumi Kawamura; Arash Pakdel; Yayoi Fukuyo; Daniel Nguyen; Sabeena Khan; Robert Arauz; Garret L Yount; Dan H Moore; Pierre-Yves Desprez; Sean D McAllister
Journal:  Cancer Res       Date:  2012-12-13       Impact factor: 12.701

7.  Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells.

Authors:  D S Mern; J Hasskarl; B Burwinkel
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

8.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

9.  Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors.

Authors:  Yuanguang Meng; Chenglei Gu; Zhiqiang Wu; Yali Zhao; Yiling Si; Xiaobing Fu; Weidong Han
Journal:  BMC Cancer       Date:  2009-03-04       Impact factor: 4.430

10.  Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers.

Authors:  Min Khine Maw; Jiro Fujimoto; Teruhiko Tamaya
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.